Total
0
Shares
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon
Managing Director, Fleta Solomon
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Little Green Pharma (LGP) is set to supply and fund a study examining the changes in quality-of-life for patients prescribed medicinal cannabis
  • The ASX-lister has been exclusively appointed to supply and fund the quality of life evaluation study (QUEST) as well as providing administration and technical advice on its products
  • Headed up by researchers at the University of Sydney, the two year study could potentially become one of the world’s largest in its kind
  • The study is currently open and planned to close in March 2022
  • Little Green Pharma shares closed the session up 3.68 per cent at 70.5 cents each

Little Green Pharma (LGP) is set to supply and fund a study examining the changes in quality-of-life for patients prescribed medicinal cannabis.

The ASX-lister has been exclusively appointed to supply medicinal cannabis oil products to enrolled patients in addition well as providing funding for study costs.

The company will also provide technical advice on its products and their administration, which was incorporated into the study design.

The quality of life evaluation study, conducted by researchers at the University of Sydney, will take place over two years and will look to recruit at lest 2100 patients by the end of June.

There is also potential to take the study internationally.

More broadly, the QUEST Initiative is tipped to be one of the world’s largest
longitudinal studies investigating the quality of life and health economics on patients with chronic disease prescribed medicinal cannabis.

During the study, patients changes and conditions will be self-reported using quality-of-life outcomes, such as patient mobility, functionality, pain or discomfort, anxiety and depression.

The study is currently open and planned to close in March 2022.

Little Green Pharma shares closed the session up 3.68 per cent at 70.5 cents each.

LGP by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Executive Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) shuffles board

Rhythm Biosciences (RHY) has restructured its board and management team, effective immediately.

" Epsilon Healthcare (ASX:EPN) extends agreement with The Valens Company

Epsilon Healthcare (EPN) has extended its agreement with The Valens Company to January 31, 2022.
Starpharma (ASX:SPL)

" Starpharma’s (ASX:SPL) nasal spray registered for sale in Vietnam

Starpharma’s (SPL) VIRALEZE product has been registered for sale in Vietnam.  
Telix Pharmaceuticals (ASX:TLX) - CEO, Christian Behrenbruch

" Telix Pharmaceuticals’ (ASX:TLX) Illuccix authorised in Brazil

Telix Pharmaceuticals (TLX) has been granted authorisation for Illuccix, the company’s lead prostate cancer imaging product.